Phase 2/3 brepocitinib trial will target moderate to severe LPP, aiming to calm inflammation and symptoms and potentially deliver the first FDA-approved systemic option.
Kristen Lo Sicco, MD
Advertisement
Kristen Lo Sicco, MD, is an associate professor of dermatology at the Ronald O. Perelman Department of Dermatology at New York University (NYU) Langone Health and the clinical director of the NYU Skin and Cancer Unit.
Articles by Kristen Lo Sicco, MD
Kristen Lo Sicco, MD, shares why scarring alopecia can’t wait as LPP demands early treatment to prevent permanent hair loss amid limited FDA-approved options.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: The Summer Skin Care "Shutdown"
2
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
3
Breakout Bulletin: July 13-July 17
4
New York Extends Nurse Practitioner Independent Practice Authority Through 2030
5